MX2021014228A - Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida. - Google Patents

Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida.

Info

Publication number
MX2021014228A
MX2021014228A MX2021014228A MX2021014228A MX2021014228A MX 2021014228 A MX2021014228 A MX 2021014228A MX 2021014228 A MX2021014228 A MX 2021014228A MX 2021014228 A MX2021014228 A MX 2021014228A MX 2021014228 A MX2021014228 A MX 2021014228A
Authority
MX
Mexico
Prior art keywords
salt forms
crystalline salt
cyclopropylmethyl
sulfonamide
quinoline
Prior art date
Application number
MX2021014228A
Other languages
English (en)
Spanish (es)
Inventor
Grove Lisa M
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2021014228A publication Critical patent/MX2021014228A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2021014228A 2019-05-22 2020-05-21 Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida. MX2021014228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851344P 2019-05-22 2019-05-22
PCT/US2020/033992 WO2020237047A1 (en) 2019-05-22 2020-05-21 Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Publications (1)

Publication Number Publication Date
MX2021014228A true MX2021014228A (es) 2022-02-21

Family

ID=71016713

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021014228A MX2021014228A (es) 2019-05-22 2020-05-21 Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida.
MX2024009648A MX2024009648A (es) 2019-05-22 2021-11-19 Formas cristalinas de sal de n-(4-(4-(ciclopropilmetil)piperazin-1 -carbonil)fenil)quinolin-8-sulfonamida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024009648A MX2024009648A (es) 2019-05-22 2021-11-19 Formas cristalinas de sal de n-(4-(4-(ciclopropilmetil)piperazin-1 -carbonil)fenil)quinolin-8-sulfonamida.

Country Status (9)

Country Link
US (1) US20230192618A1 (enExample)
EP (1) EP3972957A1 (enExample)
JP (1) JP2022533227A (enExample)
CN (2) CN118206485A (enExample)
AU (1) AU2020280045A1 (enExample)
CA (1) CA3145138A1 (enExample)
IL (1) IL288158A (enExample)
MX (2) MX2021014228A (enExample)
WO (1) WO2020237047A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240107326A (ko) 2021-11-16 2024-07-09 아지오스 파마슈티컬스 아이엔씨. Mds 관련 빈혈 및 기타 상태를 치료하기 위한 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011792D1 (de) * 2006-10-27 2011-02-17 Fmc Corp Gemeinsam aufbereitete mikrokristalline cellulose und zuckeralkohol als hilfsstoff für tablettenformulierungen
PE20120693A1 (es) * 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
UY36680A (es) * 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
KR102682430B1 (ko) * 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태

Also Published As

Publication number Publication date
MX2024009648A (es) 2024-08-19
CN114026071A (zh) 2022-02-08
JP2022533227A (ja) 2022-07-21
IL288158A (en) 2022-01-01
AU2020280045A1 (en) 2021-12-23
CN118206485A (zh) 2024-06-18
CN114026071B (zh) 2024-03-01
EP3972957A1 (en) 2022-03-30
CA3145138A1 (en) 2020-11-26
US20230192618A1 (en) 2023-06-22
WO2020237047A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
MX2022009998A (es) Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida.
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
EP4365179A3 (en) Novel rapamycin derivatives
MX2020001832A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
TN2019000192A1 (en) Pyrazole derivatives as malt1 inhibitors
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX418519B (es) Inhibidores selectivos de jak1
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
MX2020013699A (es) Derivados de pirazol como inhibidores de malt1.
CL2024000067A1 (es) Compuestos antivirales
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EA201792433A1 (ru) Производные 2-(фенилокси- или фенилтио)пиримидина в качестве гербицидов
PH12020552207A1 (en) Pyrazole derivatives as malt1 inhibitors
EA201990279A1 (ru) Гербицидные композиции, содержащие фенилпиримидины
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
PH12021552513A1 (en) Pyrrole compounds
CR20220004A (es) Nuevos compuestos heterocíclicos
TW200745066A (en) Novel PTP1B inhibitors
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
EP4706394A3 (en) Use of alkoxypyrazoles as nitrification inhibitors
GEAP202415849A (en) Crystalline salt forms of kinase inhibitor